Medivir AB announces that the company’s patent application, covering both substance claims for fostroxacitabine bralpamide and its use for liver cancer treatment, has recently been approved by the Chinese patent authority.
Medivir’s patent application for fostrox approved in China Read More »
Allgenesis Biotherapeutics Inc. announced topline data from the company’s Phase 1b clinical trial for AG-80308, a first-in-class, formyl peptide receptor agonist formulated as an aqueous solution eye drop for the treatment of Dry Eye Disease.
En lo más profundo del vasto cosmos, más allá de los límites de nuestro sistema solar, se encuentran los misteriosos “planetas errantes” o “planetas sin estrella”. Estos intrigantes objetos astronómicos, carentes de un sol que los ilumine, desaf …
Planetas errantes: El misterio de los planetas que vagan por la oscuridad del espacio Read More »
El cine ha sido durante mucho tiempo una fuente de entretenimiento y también de inspiración para explorar y comprender el mundo que nos rodea. Si eres un amante de la ciencia y buscas películas que te sumerjan en temas científicos reales, estás de suerte. En este a …
Explorando el cine científico: 5 películas inspiradoras para los amantes de la ciencia Read More »
En este Short hacemos un repaso a las profesiones que tendrán más demanda en el ámbito tecnológico tanto ahora como en un próximo futuro. …
Las profesiones con más futuro en el ámbito de la tecnología Read More »
Beactica Therapeutics AB, the Swedish precision oncology company, announced the appointment of Jarl Ulf Jungnelius M.D. to its Board of Directors.
Sensorion announces promising preliminary results from its Proof of Concept Phase 2a clinical trial of SENS-401 for residual hearing preservation following cochlear implantation.
Sensorion Reports Promising Preliminary Data from SENS-401 Phase 2a Clinical Study Read More »
Telix Pharmaceuticals Limited announces that the first patient has been dosed in a Phase II study of the Company’s carbonic anhydrase- -targeting PET/CT[1] imaging agent TLX250-CDx, exploring this potential target across a broad range of cancer indications.
Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform technology, announced the opening of its first, state-of-the-art manufacturing facility in Brisbane, Queensland.
IASO Biotechnology announced that the U.S. Food and Drug Administration has approved the Investigational New Drug application for its IASO-782 Injection for use in U.S. clinical trials for Autoimmune hematological disorders, including primary immune thrombocytopenia and warm autoimmune hemolytic anemia.
